CN106636426A - Glycopeptide antibiotic drug-resistance gene detection kit - Google Patents
Glycopeptide antibiotic drug-resistance gene detection kit Download PDFInfo
- Publication number
- CN106636426A CN106636426A CN201710024512.5A CN201710024512A CN106636426A CN 106636426 A CN106636426 A CN 106636426A CN 201710024512 A CN201710024512 A CN 201710024512A CN 106636426 A CN106636426 A CN 106636426A
- Authority
- CN
- China
- Prior art keywords
- drug resistant
- resistant gene
- glycopeptide antibiotics
- detection kit
- glycopeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 64
- 238000001514 detection method Methods 0.000 title claims abstract description 50
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 47
- MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 title abstract description 9
- 206010059866 Drug resistance Diseases 0.000 title abstract description 8
- 239000000523 sample Substances 0.000 claims abstract description 67
- 238000003908 quality control method Methods 0.000 claims abstract description 10
- 238000000034 method Methods 0.000 claims abstract description 7
- 238000002474 experimental method Methods 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 48
- 229940079593 drug Drugs 0.000 claims description 46
- 238000012360 testing method Methods 0.000 claims description 20
- 230000002068 genetic effect Effects 0.000 claims description 13
- 238000012408 PCR amplification Methods 0.000 claims description 10
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical class NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims description 8
- 230000003321 amplification Effects 0.000 claims description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- 238000009396 hybridization Methods 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003368 amide group Chemical group 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 239000011521 glass Substances 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 claims description 2
- 238000011144 upstream manufacturing Methods 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 description 8
- 230000003115 biocidal effect Effects 0.000 description 8
- 241000194033 Enterococcus Species 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 5
- 108010015899 Glycopeptides Proteins 0.000 description 4
- 102000002068 Glycopeptides Human genes 0.000 description 4
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 4
- 241000191940 Staphylococcus Species 0.000 description 3
- 241000194017 Streptococcus Species 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000000018 DNA microarray Methods 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193752 Bacillus circulans Species 0.000 description 1
- 108010065152 Coagulase Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 206010014889 Enterococcal infections Diseases 0.000 description 1
- 206010023215 Joint effusion Diseases 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 108010053950 Teicoplanin Proteins 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- DDTDNCYHLGRFBM-YZEKDTGTSA-N chembl2367892 Chemical compound CC(=O)N[C@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1O[C@@H]([C@H]1C(N[C@@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(O)C=C(C=4)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@H](CC=4C=C(Cl)C(O5)=CC=4)C(=O)N3)C(=O)N1)C(O)=O)=O)C(C=C1Cl)=CC=C1OC1=C(O[C@H]3[C@H]([C@@H](O)[C@H](O)[C@H](CO)O3)NC(C)=O)C5=CC2=C1 DDTDNCYHLGRFBM-YZEKDTGTSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- -1 formyl Amine Chemical class 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001608 teicoplanin Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 101150114434 vanA gene Proteins 0.000 description 1
- 101150037181 vanB gene Proteins 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a glycopeptide antibiotic drug-resistance gene detection kit. The glycopeptide antibiotic drug-resistance gene detection kit comprises probes 1 to 23, and corresponding sequences are shown as SEQ ID NO. 1 to SEQ ID NO. 23; the invention further discloses a method for detecting a glycopeptide antibiotic drug-resistance gene by utilizing the kit; when the glycopeptide antibiotic drug-resistance gene detection kit disclosed by the invention is used for detecting, the credibility of an experiment result needs to be evaluated at first; the detection result of the group is credible only when detection results of positive and negative quality control contrasts are positive (+) and negative (-). When the results displayed by the three probes of a detected object are consistent, whether a sample is infected by the glycopeptide antibiotic drug-resistance gene or not can be judged; when the results displayed by the three probes of the detected object are inconsistent, whether the sample to be detected is positive or negative cannot be judged, and the detection kit needs to be used for redetecting or existing other detection methods are used for further identification. The glycopeptide antibiotic drug-resistance gene detection kit is simple to operate, rapid and efficient and high in accuracy and the results are easy to read.
Description
Technical field
The invention belongs to biology field, be related to a kind of parallel probe of glycopeptide antibiotics drug resistant gene detection,
Genetic chip, kit and detection method.
Background technology
In the past few decades, antibiotic is widely used in the treatment of various infectious diseases, but also just because of antibiotic
Widely use, cause new antibiotics resistance form to continuously emerge.Enterococcus faecalis, Much's bacillus, pseudomonas aeruginosa
100 Multiple Classes of Antibiotics to clinically using have drug resistance, become the important bacterium killer for threatening human life at present.Sugar
Peptide antibiotics (G1ycopeptides, Dalbahepides) is D- alanyls-D-alanine associativity and has heptapeptide structure
A class antibiotic, to including the main pathogenic fungi such as coagulase positive or negative Staphylococcus, each group of streptococcus, enterococcus (wrap
Include enterococcus faecalis and VREF), bar bacterium, anaerobic cocci and monocyte Listeria monocytogenes are interior almost all of
Gram-positive bacteria is all active, is clinically usually used in by gram-positive bacteria especially staphylococcus, enterococcus and lung
The treatment of serious infections caused by scorching streptococcus, represents the last line of defense for treating these serious infections.
Since the enterococcus of report glycopeptide class antibiotic resistance in 1988, often go out in hospital in the world
It is existing.Have now found that 7 genotype of Main Drug-Resistant Gene VanA, VanB, VanC, VanH, VanR, VanS and VanX.Glycopeptide class resists
Raw element drug resistant gene can be carried by transposons, plasmid, be transmitted by the conjugation between bacterium, make glycopeptide resistance in enterococcus
Rate is continuously increased, and many vancomycin-resistant enterococcus also to other antibiotic (such as beta-lactam and aminoglycoside
Class antibiotic) resistance, to the clinical treatment of vancomycin-resistant enterococcal infection very big difficulty is caused.On the other hand,
It was found that some methicillin-resistant S Staphylococcus in clinic separation strains subtract to the sensitiveness of vancomycin and teicoplanin
It is weak, transferability vanB resistance determinant is found that in bargen's streptococcus clinical separation strain, it is clinically separated in Bacillus circulans
Find there is vanA gene clusters in strain, illustrate that glycopeptide drug resistant gene is not only propagated between enterococcus, and enterococcus can be transferred to
Other outer bacteriums, to following anti-infective therapy greatly threat is brought, and the glycopeptide to developing and developing efficiently and accurately is resistance to
The detection of medicine gene has great importance in clinical auxiliary treatment.
Biochip technology is the emerging biometric technology that the nineties grow up.Classify according to detection object,
The big class of genetic chip and protein-chip etc. two can be divided into.Compared with protein-chip, what genetic chip was utilized is nucleotides
Complementation between chain, high specificity, property is good.Glycopeptide antibiotics drug resistant gene chip provided by the present invention with it is traditional
Susceptibility of bacteria detection method is compared, and is directed to pathogen glycopeptide antibiotics drug resistant gene and is detected, its detection flux
The advantage such as greatly, required sample size is few, sensitivity is high, accuracy is high and specificity is good.
The content of the invention
It is an object of the present invention to provide the glycopeptide class that a species specificity is good, result is accurate, false positive rate is low, detection efficiency is high resists
Parallel probe, genetic chip, kit and detection method that raw element drug resistant gene is detected.
The present invention realizes that its purpose technical scheme is：
A kind of glycopeptide antibiotics drug resistant gene detects parallel probe, including probe 1 ~ 23, its corresponding sequence such as SEQ ID
Shown in NO.1 ~ 23.
A kind of glycopeptide antibiotics drug resistant gene detection chip, including solid phase and the probe groups described in claim 1.
Preferably, the solid phase carrier is amido modified glass substrate, nylon membrane or nitrocellulose filter.
A kind of glycopeptide antibiotics drug resistant gene detection kit, including aforesaid genetic chip.
In above-mentioned glycopeptide antibiotics drug resistant gene detection kit, also expand including the resistance to drug target gene of glycopeptide antibiotics
Increase primer pair, primer sequence is as shown in SEQ ID NO.24 ~ 39.
Preferably, CY3 fluorochrome labels are contained at 5 ' ends of the downstream primer of the primer pair.
Preferably, above-mentioned glycopeptide antibiotics drug resistant gene detection kit, also including PCR reaction systems, hybridization
Buffer solution, cleaning solution.
In above-mentioned technical proposal, the PCR reaction systems of 20 μ L include：The μ L of amplification template 2 of 50 ~ 150 ng/ μ L,
The μ L of Premix Taq 10, concentration is 8 ~ 12 μM of each 1 μ L of upstream and downstream primer, the μ L of distilled water 6.
A kind of glycopeptide antibiotics drug resistant gene detection method, is tried using the detection of aforesaid glycopeptide antibiotics drug resistant gene
Agent box detected, may determine that whether sample infects glycopeptide when the testing result that three probes of detection object show is consistent
Class antibiotic resistance genes；When the testing result that three probes of detection object show is inconsistent, it is impossible to judge that this treats test sample
Product are positive or negative, it is proposed that detected again using the detection kit or further tested using existing other detection methods
Card.
Preferably, pcr amplification reaction program is 95 DEG C of 5 min；95℃10 s、55℃ 30 s、72℃30 s、30
Individual circulation；72℃ 10 min.
The invention has the beneficial effects as follows：Each drug resistant gene designs the probe of 3 high specifics, when the detection of 3 probes
The index is just judged when being as a result the positive for positive, the accuracy and accuracy of product can be greatly improved, other are reduced
The false positive issue that method easily occurs；The present invention is carried out by round pcr to pathogen glycopeptide antibiotics drug resistant gene group
Amplification, the specificity of detection is high, and amplified production is hybridized with the oligonucleotide probe on biochip, is marked by CY3
The reverse amplimers of PCR detect results of hybridization.Simple to operate, result is readable, meets the Site Detection demand such as medical treatment, is clinical doctor
That the whether infected glycopeptide antibiotics drug resistant gene of raw quick diagnosis patient is provided is convenient, theoretical foundation fast and accurately,
With wide clinical practice market potential.
Description of the drawings
Fig. 1 detects the genetic chip schematic diagram of glycopeptide antibiotics drug resistant gene.
PCR primer electrophoretic band figure after the amplification of Fig. 2 testing sample glycopeptide antibiotics drug resistant gene；Marker DL2000
（TAKARA）.
Specific embodiment
Below in conjunction with accompanying drawing, the preferred embodiments of the present invention are described in detail.It is unreceipted concrete in embodiment
The experimental technique of condition, generally according to normal condition, such as Molecular Cloning:A Laboratory guide（The third edition, J. Pehanorm Brookers etc.
Write）Described in condition, or according to the condition proposed by manufacturer.Following examples are used to illustrate the present invention, but are not used in
Limit the scope of the present invention.
The purpose fragment primer of embodiment 1 is designed with probe
Search gene order VanA, VanB of glycopeptide antibiotics drug resistant gene in ncbi database, VanC, VanH, VanR,
VanS and VanX, using chip probe design software（ArrayDesigner4.2）3 probes are designed for each drug resistant gene,
The probe of another design 16sRNA genes is used as positive quality control probe（PC）With one section of probe of random synthesis as negative Quality Control probe
（NC）, correspondence probe sequence is as shown in SEQ ID NO .1 ~ 23.
Using NCBI Photographing On-line softwares（Primer-BLAST）Design VanA, VanB, VanC, VanH, VanR, VanS and
The pcr amplification primer thing of VanX genes, while designing the amplimer of 16sRNA genes.In order that chip results are more directly perceived,
Reverse amplimer（R）5 ' ends are marked with CY3 fluorescent dyes, corresponding primer sequence such as SEQ ID NO .24 ~ 39 institute
Show.
The preparation of the chip of embodiment 2
By the parallel probe in embodiment 1 according to the order point sample of table 1 in amido modified glass substrate, obtain containing probe
Genetic chip（As shown in Figure 1）.Concentration and probe concentration is 30 μM, 0.2 μ L of each point, then 80 DEG C of 1.5 h of incubation.
The detection method of embodiment 3
1st, testing sample genome is extracted
Using bacterial genomes DNA extraction kit, according to the genome conduct that testing sample is extracted the step of operational manual
Amplification template.
2nd, PCR amplifications purpose fragment
Grope through many experiments, determine the target gene PCR amplification system and PCR response procedures of Van detections.By each Van base
Because of the primer of VanA, VanB, VanC, VanH, VanR, VanS, VanX and 16SrRNA amplification, PCR amplification buffers are prepared respectively
System, cumulative volume be 20 μ L PCR amplification system in be respectively containing reagent：μ L, F primers of Premix LATaq 10（10μM）
1 μ L, F primers（10 μM）1 μ L, the amplification μ L of template 2, the μ L of distilled water 6.
PCR response procedures are：95℃ 5 min；95 DEG C of 10 s, 55 DEG C of 30 s, 72 DEG C of 30 s, 30 circulations；72℃ 10
min。
3rd, PCR primer and chip hybridization
Operate in accordance with the following steps：
A. on the genetic chip for preparing in example 2, by the VanA of testing sample, VanB, VanC, VanH, VanR,
The pcr amplification product of VanS, VanX and 16SrRNA is mixed and point sample is in the detect tank of chip, the PCR primer point of VanA primers
Other point on VanA-1, VanA-2, VanA-3 probe, divide by the PCR primer of VanB, VanC, VanH, VanR, VanS, VanX primer
To on probe, the PCR primer of 16sRNA primers puts respectively positive quality control probe to other corresponding points（PC）With negative Quality Control probe
(NC).Concretely comprise the following steps：95 DEG C of PCR primer is unwind 5 minutes, is immediately placed on ice, PCR primer and hybridization buffer（50% formyl
Amine, 10 × SSC, 0.2%SDS）Equal-volume mixes, and selects 10 μ L mixed liquors per hole, in wet box, in 60 DEG C of hybridization incubations 2 hours；
B. the genetic chip after incubation is taken out, cleaning solution is used（0.3 × SSC buffer solutions）Cleaning 3 times；
C. chip is put into laser co-focusing detector（GenePix）Chip is scanned at 650 nm；Software analysis fluorescence signal
Intensity level, provides result.
Embodiment 4 detects testing sample
5 parts of the sample of glycopeptide antibiotics drug-resistant bacteria infection is obtained from Third Military Medical University（Effusion of knee joint）, sugar-free peptides
Antibiotic resistance genes infect 1 part of sample（Control group）.Extract treat test sample respectively according to the primer and method in embodiment 1 and 3
The genome of product, after entering performing PCR amplification, is detected using the genetic chip in embodiment 2.Product electrophoresis after PCR amplifications
Band shows that the amplimer specificity of present invention design is high, can special, delicately amplify target gene（As shown in Figure 2）.
For the sample of bacterium infection, laser co-focusing detector（GenePix）Chip, probe points are scanned at 650 nm
Fluorescence signal is stronger（More than 20）, it is designated as（+）, fluorescence signal is weaker（Less than 5）, then it is designated as（-）, fluorescence signal intensity is difficult to point
Distinguish（5~20）Then it is designated as（*）.Positive and negative Quality Control control is designed in detection simultaneously, only when positive and negative Quality Control control
Testing result is divided into not positive simultaneously（+）And feminine gender（-）, just think that this group of testing result is credible.
When judging testing result, when 3 probes of VanA, VanB, VanC, VanH, VanR, VanS, VanX gene show
The sample is just judged when showing the positive with the drug resistant gene, if wherein some or two probes show positive, is tackled
The detection sample detects that 3 probe results unanimously just must can accept and believe the testing result again.3 probe in detecting results are inconsistent
When, it is possible to use existing other technologies（Such as elisa methods）Further detection checking.Testing result is as shown in table 2.
The pattern detection result of table 2
As a result it is shown as positive quality control control and is the positive（+）, negative Quality Control control is feminine gender（-）, illustrate that testing result can
Letter.The infection of glycopeptide antibiotics drug resistant gene is detected in wherein 5 parts samples, sample 1 is by glycopeptide antibiotics drug resistant gene
VanA infects, and sample 2 is infected by glycopeptide antibiotics drug resistant gene VanR, and sample 3 is by glycopeptide antibiotics drug resistant gene VanX
Infection, sample 4 is infected by glycopeptide antibiotics drug resistant gene VanX, and sample 5 is infected by glycopeptide antibiotics drug resistant gene VanR；
Check sample is not detected by glycopeptide antibiotics drug resistant gene, is consistent with actual clinical sample information situation.
Probe disclosed by the invention, genetic chip, kit, specificity is high, result is very accurate, and detection is quick, work
Efficiency high, it is simple to operate, meet the Site Detection demand of hospital etc., providing for the drug-resistant bacteria infection of diagnosis glycopeptide antibiotics can
The experimental basis for leaning on.
SEQUENCE LISTING
<110>Chongqing prestige this rise biological medicine science and technology limited Company
<120>A kind of glycopeptide antibiotics drug resistant gene detection kit
<130> 2017
<160> 39
<170> PatentIn version 3.5
<210> 1
<211> 45
<212> DNA
<213>Artificial sequence
<400> 1
tttttttttt ttttttgacg tgaaaccggg cagagtattg acttc 45
<210> 2
<211> 45
<212> DNA
<213>Artificial sequence
<400> 2
tttttttttt tttttgattt ggtccacctc gccaacagct aacgc 45
<210> 3
<211> 45
<212> DNA
<213>Artificial sequence
<400> 3
tttttttttt tttttattaa taacccaaaa ggcgggagta gctat 45
<210> 4
<211> 47
<212> DNA
<213>Artificial sequence
<400> 4
tttttttttt tttttttttt gaattgtctg gtatccccta tgtaggc 47
<210> 5
<211> 47
<212> DNA
<213>Artificial sequence
<400> 5
tttttttttt tttttttccg gcacggtcag gttcgtcctt tggcgta 47
<210> 6
<211> 45
<212> DNA
<213>Artificial sequence
<400> 6
tttttttttt tttttgatca aatccggttg agccacggta tcttc 45
<210> 7
<211> 45
<212> DNA
<213>Artificial sequence
<400> 7
tttttttttt tttttcataa acagaaaata cagccgctat tcgaa 45
<210> 8
<211> 45
<212> DNA
<213>Artificial sequence
<400> 8
tttttttttt ttttttctgc cttatgtatg aacaaatggc tgctg 45
<210> 9
<211> 45
<212> DNA
<213>Artificial sequence
<400> 9
tttttttttt tttttggcaa cgactctttg actgtcggtg cttgt 45
<210> 10
<211> 45
<212> DNA
<213>Artificial sequence
<400> 10
tttttttttt tttttggtgt gaaatatatt tctacccgaa gcatc 45
<210> 11
<211> 45
<212> DNA
<213>Artificial sequence
<400> 11
tttttttttt tttttgtggt gggaacgggc cagataggca aagcg 45
<210> 12
<211> 45
<212> DNA
<213>Artificial sequence
<400> 12
tttttttttt tttttattat cagccacgaa caaatacaga gaatg 45
<210> 13
<211> 45
<212> DNA
<213>Artificial sequence
<400> 13
tttttttttt tttttatatt ggacatcatg cttcccggca caagc 45
<210> 14
<211> 45
<212> DNA
<213>Artificial sequence
<400> 14
tttttttttt tttttgggtt aacaatcggc gcggatgatt atata 45
<210> 15
<211> 45
<212> DNA
<213>Artificial sequence
<400> 15
tttttttttt tttttgaaaa tgttatcgtc cactccggcc ttgtc 45
<210> 16
<211> 45
<212> DNA
<213>Artificial sequence
<400> 16
tttttttttt tttttgatgt acttattcag aacgaagata aacaa 45
<210> 17
<211> 45
<212> DNA
<213>Artificial sequence
<400> 17
tttttttttt tttttggaaa acaggcggtt attcacgccc ccgag 45
<210> 18
<211> 45
<212> DNA
<213>Artificial sequence
<400> 18
tttttttttt tttttgccga acaaagaaaa aatgacgttg ttatg 45
<210> 19
<211> 45
<212> DNA
<213>Artificial sequence
<400> 19
tttttttttt tttttttgaa ggcaaaagaa ctggctgcta cccaa 45
<210> 20
<211> 45
<212> DNA
<213>Artificial sequence
<400> 20
tttttttttt tttttgcttc aaaatcaagc catagccgcg gcagt 45
<210> 21
<211> 45
<212> DNA
<213>Artificial sequence
<400> 21
tttttttttt tttttgcggc aaatggaata tcatgcaatg aagcg 45
<210> 22
<211> 34
<212> DNA
<213>Artificial sequence
<400> 22
tttttttttt tttttccgat agtgaaccag tacc 34
<210> 23
<211> 38
<212> DNA
<213>Artificial sequence
<400> 23
tttttttttt tttttctatc tagctagcta gctagcta 38
<210> 24
<211> 25
<212> DNA
<213>Artificial sequence
<400> 24
cgatcaagcg gtcaatcagt tcggg 25
<210> 25
<211> 24
<212> DNA
<213>Artificial sequence
<400> 25
cctctgagca acccccaaac agta 24
<210> 26
<211> 29
<212> DNA
<213>Artificial sequence
<400> 26
gcggttgctc ggaggaacat gatgtgtcg 29
<210> 27
<211> 24
<212> DNA
<213>Artificial sequence
<400> 27
tatcgccaat gtaatcaggc tgtc 24
<210> 28
<211> 27
<212> DNA
<213>Artificial sequence
<400> 28
attcaccgga atacaccgtt tctttag 27
<210> 29
<211> 26
<212> DNA
<213>Artificial sequence
<400> 29
tcttgatagg ataagccgac cgctgc 26
<210> 30
<211> 25
<212> DNA
<213>Artificial sequence
<400> 30
tcggcattac tgtttatgga tgtga 25
<210> 31
<211> 28
<212> DNA
<213>Artificial sequence
<400> 31
ctcctgtctc ctttcaaaat ccaaacag 28
<210> 32
<211> 26
<212> DNA
<213>Artificial sequence
<400> 32
gtggatgatg aacatgaaat tgccga 26
<210> 33
<211> 25
<212> DNA
<213>Artificial sequence
<400> 33
aaccaagtct ggcatcgctg gaagc 25
<210> 34
<211> 25
<212> DNA
<213>Artificial sequence
<400> 34
attcgtgttg tatattcgtt caatg 25
<210> 35
<211> 25
<212> DNA
<213>Artificial sequence
<400> 35
aaccaagtct ggcatcgctg gaagc 25
<210> 36
<211> 19
<212> DNA
<213>Artificial sequence
<400> 36
gatgaaatag tacacggtg 19
<210> 37
<211> 21
<212> DNA
<213>Artificial sequence
<400> 37
ggggaaatca aaatagctat t 21
<210> 38
<211> 21
<212> DNA
<213>Artificial sequence
<400> 38
gagagtttga tyctggctca g 21
<210> 39
<211> 20
<212> DNA
<213>Artificial sequence
<400> 39
aaggaggtga tccarccgca 20
Claims (10)
1. a kind of glycopeptide antibiotics drug resistant gene detects parallel probe, it is characterised in that：Including probe 1 ~ 23, its corresponding sequence
Row are as shown in SEQ ID NO.1 ~ 23.
2. a kind of glycopeptide antibiotics drug resistant gene detects genetic chip, it is characterised in that：Will including solid phase support and right
Seek the probe groups described in 1.
3. glycopeptide antibiotics drug resistant gene as claimed in claim 2 detects genetic chip, it is characterised in that：The solid phase is carried
Body is amido modified glass substrate.
4. a kind of glycopeptide antibiotics drug resistant gene detection kit, it is characterised in that：Including the base described in Claims 2 or 3
Because of chip.
5. glycopeptide antibiotics drug resistant gene detection kit as claimed in claim 4, it is characterised in that：Also include glycopeptide class
Antibiotics resistance target gene amplimer pair, primer sequence is as shown in SEQ ID NO.24 ~ 39.
6. glycopeptide antibiotics drug resistant gene detection kit as claimed in claim 5, it is characterised in that：The primer pair
Contain CY3 fluorochrome labels in 5 ' ends of downstream primer.
7. the glycopeptide antibiotics drug resistant gene detection kit as described in claim 4-6, it is characterised in that：Also include PCR
Reaction system, hybridization buffer, cleaning solution.
8. glycopeptide antibiotics drug resistant gene detection kit as claimed in claim 7, it is characterised in that：PCR reaction systems
Including：The μ L of amplification template 2 of 50 ~ 150 ng/ μ L, the μ L of Premix Taq 10, concentration is 10 μM of each 1 μ of upstream and downstream primer
L, the μ L of distilled water 6.
9. a kind of detection method of glycopeptide antibiotics drug resistant gene, it is characterised in that：Usage right requires 4 to 8 any one institutes
The glycopeptide antibiotics drug resistant gene detection kit stated is detected；First to carry out reliable experiment result degree assessment, only when
The testing result of positive and negative Quality Control control is divided into not positive simultaneously（+）And feminine gender（-）, just think that this group of testing result can
Letter；May determine that whether sample is felt when the testing result that 3 probes of any one drug resistant gene for detecting sample show is consistent
Dye glycopeptide antibiotics drug resistant gene；When the testing result for detecting that any 3 probes of drug resistant gene of sample show is inconsistent, no
The testing sample can be judged for positive or negative, it is proposed that detect again using the detection kit or using existing other detections
Method is further verified.
10. the detection method of glycopeptide antibiotics drug resistant gene as claimed in claim 9, it is characterised in that：Pcr amplification reaction
Program is 95 DEG C of 5 min；95 DEG C of 10 s, 40 DEG C of 30 s, 72 DEG C of 90 s, 30 circulations；72℃ 10 min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710024512.5A CN106636426A (en) | 2017-01-13 | 2017-01-13 | Glycopeptide antibiotic drug-resistance gene detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710024512.5A CN106636426A (en) | 2017-01-13 | 2017-01-13 | Glycopeptide antibiotic drug-resistance gene detection kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106636426A true CN106636426A (en) | 2017-05-10 |
Family
ID=58844287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710024512.5A Pending CN106636426A (en) | 2017-01-13 | 2017-01-13 | Glycopeptide antibiotic drug-resistance gene detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106636426A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110055308A (en) * | 2019-04-27 | 2019-07-26 | 浙江大学 | Detect the specific primer of four kinds of glycopeptide class Drug-resistant genes and probe combinations and application in Enterococcus |
| CN110066882A (en) * | 2019-04-27 | 2019-07-30 | 浙江大学 | Detect the specific primer of five kinds of glycopeptide class Drug-resistant genes and probe combinations and application in Enterococcus |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001012803A2 (en) * | 1999-08-17 | 2001-02-22 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for restoring antibiotic susceptibility in glycopeptide-resistant enterococcus |
| CN1246474C (en) * | 2001-07-13 | 2006-03-22 | 刘元 | Detection to drug tolerant gene by gene chip technique |
| CN105925700A (en) * | 2016-06-06 | 2016-09-07 | 重庆威斯腾生物医药科技有限责任公司 | Toxoplasma detecting parallel probes, gene chip, kit and detection method |
-
2017
- 2017-01-13 CN CN201710024512.5A patent/CN106636426A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001012803A2 (en) * | 1999-08-17 | 2001-02-22 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for restoring antibiotic susceptibility in glycopeptide-resistant enterococcus |
| CN1246474C (en) * | 2001-07-13 | 2006-03-22 | 刘元 | Detection to drug tolerant gene by gene chip technique |
| CN105925700A (en) * | 2016-06-06 | 2016-09-07 | 重庆威斯腾生物医药科技有限责任公司 | Toxoplasma detecting parallel probes, gene chip, kit and detection method |
Non-Patent Citations (3)
| Title |
|---|
| A MIELE等: "Use of primers selective for vancomycin resistance genes to determine van genotype in enterococci and to study gene organization in VanA isolates", 《ANTIMICROB AGENTS CHEMOTHER》 * |
| G KLEIN等: "Exclusion of vanA, vanB and vanC type glycopeptide resistance in strains of Lactobacillus reuteri and Lactobacillus rhamnosus used as probiotics by polymerase chain reaction and hybridization methods", 《J APPL MICROBIOL》 * |
| 王雪松等: "1株VanA型VRE菌株的鉴定及耐药诱导特性研究", 《军事医学》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110055308A (en) * | 2019-04-27 | 2019-07-26 | 浙江大学 | Detect the specific primer of four kinds of glycopeptide class Drug-resistant genes and probe combinations and application in Enterococcus |
| CN110066882A (en) * | 2019-04-27 | 2019-07-30 | 浙江大学 | Detect the specific primer of five kinds of glycopeptide class Drug-resistant genes and probe combinations and application in Enterococcus |
| CN110066882B (en) * | 2019-04-27 | 2020-08-07 | 浙江大学 | Specific primer and probe combination for detecting drug resistance genes of five glycopeptide drugs in enterococcus and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Redondo et al. | A novel RT-PCR for the detection of Helicobacter pylori and identification of clarithromycin resistance mediated by mutations in the 23S rRNA gene | |
| CN110923298B (en) | Primer probe system, kit and method for simultaneously detecting multiple drug-resistant genes | |
| CN106893782B (en) | It is a kind of to detect and identify cryptococcal target gene, primer and probe and kit | |
| CN103173561B (en) | Detect primer and the probe of gene mecA in methicillin-resistant staphylococcus aureus | |
| Frickmann et al. | Rapid discrimination of Haemophilus influenzae, H. parainfluenzae, and H. haemolyticus by fluorescence in situ hybridization (FISH) and two matrix-assisted laser-desorption-ionization time-of-flight mass spectrometry (MALDI-TOF-MS) platforms | |
| CN116042880A (en) | Polymerase chain reaction primer and probe of mycobacterium tuberculosis | |
| CN105063218B (en) | The multiple quantitative PCR reagent kit of the difficult culture identification bacterium of four kinds of fast joint inspection | |
| CN103060455A (en) | Detection gene chip for helicobacter pylori infection individualized treatment and application of gene chip | |
| Nomura et al. | New colony multiplex PCR assays for the detection and discrimination of vancomycin-resistant enterococcal species | |
| Wu et al. | Fluorescence in situ hybridization rapidly detects three different pathogenic bacteria in urinary tract infection samples | |
| CN104212901A (en) | Composition for detecting drug resistance of staphylococcus aureus | |
| CN110669851A (en) | Primer and/or probe composition for detecting cocci causing bloodstream infections and use thereof | |
| CN107523619A (en) | The PCR detection kit of drug-fast bacteria comprising mcr genes and its application | |
| CN106636426A (en) | Glycopeptide antibiotic drug-resistance gene detection kit | |
| CN109402276A (en) | A kind of primer sets, kit and application for Multi-drug resistant Acinetobacter baumannii LAMP detection | |
| CN106754905A (en) | LAMP primer composition and its application for detecting methicillin-resistant staphylococcus aureus | |
| CN104313167A (en) | Primers and method for rapidly identifying group B streptococcus and detecting drug resistance thereof and primer application | |
| CN106048051B (en) | A kind of candida krusei fluorescence PCR detection reagent kit | |
| CN104031994B (en) | Visualize Pathogen test chip and its preparation method and application | |
| CN107988400A (en) | Detect the reagent set of staphylococcus haemolyticus | |
| CN107523620A (en) | PCR detection kit and its application comprising production NDM drug-fast bacterias | |
| Shivekar et al. | Molecular basis for erythromycin resistance in group A Streptococcus isolated from skin and soft tissue infections | |
| CN110923344A (en) | Staphylococcus aureus and methicillin-resistant staphylococcus aureus drug-resistant gene mecA detection kit and application thereof | |
| CN106636355A (en) | Parallel probe, gene chip, kit and method for tetracycline-resistant gene detection | |
| CN108048583A (en) | A kind of probe, genetic chip and kit for pseudomonas aeruginosa detection of nucleic acids |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170510 |
|
| RJ01 | Rejection of invention patent application after publication |